Sanjivani Paranteral Limited has announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 14, 2026, with the statutory auditors issuing an unmodified opinion on the audited financial results. In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company also published an advertisement in The Financial Express (English) and Pratkal (Marathi), and separately made available the audio recording of its earnings call — held on May 15, 2026 — on its website pursuant to Regulation 30 of the SEBI Listing Regulations.

Consolidated Financial Performance

On a consolidated basis, Sanjivani Paranteral reported a net profit after tax of ₹669.38 lacs for FY26, compared to ₹809.43 lacs in the previous year. Revenue from operations stood at ₹6,975.64 lacs for the full year, against ₹7,131.21 lacs in FY25. For the quarter ended March 31, 2026, consolidated net profit after tax was ₹54.85 lacs on revenue from operations of ₹1,380.91 lacs.

Standalone Financial Performance

On a standalone basis, the company reported a net profit after tax of ₹692.32 lacs for FY26, compared to ₹810.18 lacs in FY25. Standalone revenue from operations for the full year stood at ₹6,600.11 lacs, against ₹7,131.21 lacs in the prior year. For Q4 FY26, standalone net profit after tax was ₹93.74 lacs on revenue from operations of ₹1,125.81 lacs.

Operational Highlights

The company's quarterly performance was impacted by temporary logistical disruptions in certain export markets, resulting in shipment delays and an unfavourable product mix, which affected EBITDA margins during the quarter. The company also had finished goods worth approximately ₹6 crore ready for dispatch that could not be shipped during March due to ongoing geopolitical tensions impacting trade routes across the US/Israel-Iraq region. Despite these challenges, the company maintained strong operational discipline, achieving a 242 bps reduction in employee and operating expenses as a percentage of revenue. Shipment movement has since normalised, supported by strengthened compliance and logistics processes.

The Pune IV Fluids Plant continues to witness gradual scale-up with improving commercial traction and increasing customer engagement, progressing in line with the planned ramp-up schedule. The company is currently focused on obtaining additional formulation approvals, customer registrations, and institutional empanelments to support higher capacity utilisation. Additionally, the Prague plant achieved commercial commencement and recorded initial shipments of approximately USD 0.5 million, with management expecting the facility to gradually contribute meaningfully to profitability and operating margins as utilisation levels improve.

Segment-wise and Market-wise Performance

For FY26, the Injectables segment contributed 53.45% with revenue of ₹346.15 lacs (in ₹ mn terms: ₹346.15 mn equivalent basis as previously reported). Tablets revenue grew by approximately 7.5% YoY to ₹279.14 mn, contributing 43.10% to revenue from operations, while Nutraceuticals revenue stood at ₹22.35 mn, accounting for 3.45%. On the market front, exports including incentives contributed 78.50% of revenue from operations at ₹508 mn, while domestic markets contributed 21.50%. Core markets including CIS, Middle East & Africa, and Latin America accounted for approximately 77.01% of revenue from operations, amounting to approximately ₹498.75 mn.

Regulatory Compliance

In line with regulatory requirements, the company filed a disclosure with BSE Limited on May 16, 2026, confirming publication of the audited financial results advertisement in The Financial Express (English) and Pratkal (Marathi), pursuant to Regulation 47 of the SEBI Listing Regulations. The earnings call audio recording held on May 15, 2026, covering the audited financial results for Q4 and full year ended March 31, 2026, was also made available on the company's website pursuant to Regulation 30 of the SEBI Listing Regulations.

Sanjivani Paranteral has informed BSE Limited of an upcoming Board of Directors meeting, scheduled for Thursday, May 14, 2026, at the company's registered office located at 205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai – 400 078, Maharashtra. The intimation was filed on May 5, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Board Meeting

The board meeting has been convened to transact key business matters. The following table outlines the primary agenda items:

The approved results will be submitted to the exchange upon conclusion of the board meeting.

Trading Window Closure

In line with the company's Insider Trading Code, the trading window for dealing in the shares of the company is currently closed and will remain closed until 48 hours after the announcement of the audited financial results for the quarter and financial year ended March 31, 2026. This measure is in accordance with applicable regulatory requirements governing insider trading.

Filing Details

The intimation was signed by Ravikumar Bogham, Company Secretary and Compliance Officer of Sanjivani Paranteral, and addressed to BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. The filing underscores the company's compliance with its disclosure obligations under SEBI's listing regulations.